Central retinal artery occlusion (CRAO) is a devastating ophthalmologic and neurological emergency representing an acute ischemic stroke of the eye3,4. Caused predominantly by thromboembolic or atherosclerotic occlusion of the central retinal artery—the primary blood supply to the inner two-thirds of the retina—CRAO results in abrupt, profound, and painless monocular visual loss4,7. Because the retina has exceptionally high metabolic activity and relies entirely on end-artery perfusion, irreversible neuronal injury and infarction occur within minutes of complete circulatory arrest5,7. Clinically, CRAO is distinguished by a striking constellation of signs including a relative afferent pupillary defect, a pale, edematous retina on fundoscopic examination, and a pathognomonic foveal 'cherry-red spot'1. Beyond immediate visual morbidity, CRAO serves as a critical systemic harbinger of severe atherosclerotic cardiovascular and cerebrovascular disease, requiring urgent multidisciplinary evaluation identical to that of acute cerebral infarction3,4.

1. Etiology & Risk Factors

  • Atherosclerosis and Thromboembolism: The most common mechanism in non-arteritic CRAO (NA-CRAO) involves cholesterol plaques (Hollenhorst plaques), platelet-fibrin emboli, or calcific emboli originating from ipsilateral carotid artery atherosclerosis or cardiac valves1,3.
  • Giant Cell Arteritis (GCA): Arteritic CRAO accounts for approximately 5% to 10% of cases and results from granulomatous panarteritis of the ophthalmic and posterior ciliary branches in patients typically over 50 years of age, representing a medical emergency that threatens bilateral vision1,2.
  • Cardiovascular Risk Factors: Hypertension, diabetes mellitus, dyslipidemia, cigarette smoking, and metabolic syndrome significantly increase endothelial damage and plaque formation within the carotid-cardiac axis3,4.
  • Hypercoagulable States: Inherited or acquired thrombophilias (e.g., antiphospholipid syndrome, factor V Leiden, hyperhomocysteinemia) and systemic inflammatory disorders (e.g., systemic lupus erythematosus, polyarteritis nodosa) predispose to in-situ thrombosis1,7.
  • Increased Intraocular Pressure & Hemodynamic Mechanisms: Severe systemic hypotension, vasospasm (e.g., migraine-associated or following sympathomimetic drug use), and acute elevations in intraocular pressure (such as during prone positioning in major spinal surgery) can precipitate closure of the central retinal artery1,5.

2. Pathophysiology

The central retinal artery, a direct branch of the ophthalmic artery, enters the optic nerve sheath approximately 10 millimeters posterior to the globe and supplies the inner retinal layers (from the internal limiting membrane to the inner nuclear layer). When this vessel is abruptly occluded, immediate cessation of microvascular perfusion triggers a precipitous drop in tissue oxygen tension and ATP depletion. This energy failure disrupts cellular sodium-potassium pumps, leading to cytotoxic cellular edema within the ganglion cell and nerve fiber layers, which manifests clinically as a milky-white, opaque, edematous retina on fundoscopy1,7. Conversely, the fovea centralis—the region responsible for sharp central vision—lacks inner retinal layers and receives its sole blood supply from the underlying choriocapillaris via the short posterior ciliary arteries. Because the choroidal circulation remains uninterrupted during standard CRAO, the underlying choroid continues to perfuse the thin, avascular foveola, creating the classic contrast of a bright red foveal center surrounded by ischemic, pale retinal tissue (the 'cherry-red spot')1,4. If ischemia persists beyond 90 to 240 minutes, permanent coagulative necrosis of the inner retina ensues, resulting in irreversible vision loss and permanent optic atrophy5,7.

Central retinal artery occlusion (CRAO) — Pathophysiological Cascade & Clinical Flowchart 1 Trigger / Primary Insult Thromboembolic plaque or giant cell arteritis occlusion of the central retinal artery 2 Cellular / Pathophysiological Cascade Acute cessation of blood flow and profound ischemic necrosis of the inner retinal layers 3 Target Organ / Structural Change Retinal edema with preservation of the thin, vascularly supplied foveola 4 Hallmark Clinical & Diagnostic Manifestation Sudden painless blindness, RAPD, and a pale retina with a cherry-red spot 5 Complications if Untreated & Therapeutic Target Permanent vision loss and neovascular glaucoma requiring hyperacute reperfusion

3. Clinical Presentation & Classic Clinical Signs

  • History & Cardinal Symptoms: Patients present with sudden, profound, painless unilateral visual loss that typically develops over seconds. Some individuals describe transient episodes of amaurosis fugax preceding the permanent occlusion. Central visual acuity is severely depressed, frequently limited to counting fingers, hand movements, or bare light perception, though a small minority may retain a small patch of functional vision if a cilioretinal artery spares the papillomacular bundle1,2.
  • Physical Examination & Named Clinical Signs:
    • Relative Afferent Pupillary Defect (RAPD / Marcus Gunn Pupil): A robust sign of asymmetric optic nerve and retinal input, demonstrating paradoxical dilation of the affected eye when light is swung from the contralateral eye1.
    • Cherry-Red Spot: A prominent, distinct bright red fovea standing out against a pale, whitened, edematous posterior pole1,3.
    • Cattle-Trucking (Segmentation): Discontinuous columns of flowing blood cells within retinal arterioles caused by sluggish, fragmented blood flow under high downstream resistance1.
    • Hollenhorst Plaques: Refractile, yellow cholesterol crystals visible at arteriolar bifurcations in roughly 20% of non-arteritic cases1.

4. Diagnostic Workup & Interpretation (Laboratory, Imaging & ECG/Pathology)

Diagnostic Modality / Test Expected Clinical & Radiological / Laboratory Finding
Gold-Standard InvestigationUrgent Dilated Fundoscopy reveals a pale, edematous retina with a foveal cherry-red spot and attenuated arterioles; Optical Coherence Tomography (OCT) demonstrates marked inner retinal thickening and hyperreflectivity acutely, progressing to profound inner retinal atrophy chronically1,5.
Laboratory PanelImmediate ESR and CRP to screen for Giant Cell Arteritis in patients over 50 years; complete blood count, lipid profile, fasting blood glucose or HbA1c, and hypercoagulability workup in younger cohorts1,3.
Imaging / Radiology (X-ray, US, CT, MRI)Carotid Duplex Ultrasound to identify significant internal carotid artery stenosis (>50%); Echocardiography (transthoracic and transesophageal) and Holter monitor/ECG to rule out cardiogenic sources of embolism such as atrial fibrillation or valvular vegetations1,3.
ECG / Histopathology / Procedural12-lead ECG to evaluate for acute myocardial infarction or cardiac conduction abnormalities associated with systemic vascular disease; temporal artery biopsy remains the definitive gold standard if GCA is suspected1,2.

5. Staging, Classification & Clinical Scoring Systems

Criterion / Stage / Score Component Clinical Threshold, Points & Management Implication
Non-Arteritic CRAO (NA-CRAO)Most common subtype linked to systemic atherosclerosis and thromboembolism; spontaneous visual improvement occurs in ~22% of baseline counting-finger cases within 7 days2.
Transient NA-CRAOIntermittent or partially resolving occlusion characterized by high rates (~82%) of spontaneous visual recovery; requires urgent embolic evaluation to prevent permanent subsequent infarction2.
NA-CRAO with Cilioretinal Artery SparingPresent in ~15-30% of individuals who possess an accessory cilioretinal artery branching from the choroidal circulation; spares central visual acuity in ~67% of cases2.
Arteritic CRAO (Giant Cell Arteritis)Ophthalmic emergency marked by severe visual loss, jaw claudication, temporal headache, elevated ESR/CRP; requires immediate high-dose systemic steroids to protect the contralateral eye1,2.

6. Differential Diagnosis

Differential Condition Distinguishing Clinical, Biochemical & Imaging Features
Central Retinal Vein Occlusion (CRVO)Presents with subacute visual loss, tortuous dilated retinal veins throughout all quadrants ('blood-and-thunder' fundus), extensive retinal hemorrhages, and cotton-wool spots, contrasting with the pale ischemic retina of CRAO1.
Acute Retinal Necrosis (ARN)Viral retinopathy characterized by painful red eye, vitritis, prominent anterior chamber inflammation, and peripheral yellowish-white necrotic patches of retina rather than acute painless arteriolar shutdown1.
Commotio Retinae (Berlin Edema)History of recent blunt ocular trauma causing outer retinal and photoreceptor disruption, manifesting as transient milky retinal whitening without cherry-red spot or vascular segmentation1.
Optic NeuritisPresents with painful monocular vision loss, impaired color vision, and relative afferent pupillary defect, but fundoscopy typically reveals a normal optic disc (retrobulbar) or mild papillitis without a cherry-red spot or retinal edema1.

7. Management & Treatment Protocol

  • Initial Stabilization & Resuscitation: Immediate activation of an emergency hyperacute stroke pathway. Determine exact symptom onset time to assess eligibility for acute thrombolytic therapy (<4.5 hours)3,5.
  • First-Line Medical / Pharmacological Therapy (with exact adult dosing):
    • Arteritic Exclusion & Steroid Therapy: If GCA is suspected in patients >50 years, administer intravenous Methylprednisolone (1,000 mg IV daily for 3 days) immediately before awaiting biopsy confirmation1.
    • Intraocular Pressure Reduction: Administer IV Acetazolamide (500 mg slow IV push) or topical agents (e.g., Timolol 0.5% drops) to lower intraocular pressure, theoretically forcing emboli downstream into smaller vascular branches1,5.
    • Acute Thrombolysis: In selected hyperacute presentations within 4.5 hours, intravenous recombinant tissue-type plasminogen activator (Alteplase at 0.9 mg/kg, max 90 mg; 10% given as bolus over 1 minute, remainder infused over 60 minutes) or Tenecteplase may be considered under stroke team protocols5,6.
  • Surgical / Interventional Indications: Conservative measures such as ocular massage (manual compression and release of the globe) and anterior chamber paracentesis lack robust evidence of efficacy and are generally discouraged in favor of hyperacute stroke protocols and secondary vascular risk reduction1,5.

8. Complications & Prognosis

  • Visual Morbidity: Permanent, severe visual impairment is common, with the majority of untreated non-arteritic cases remaining legally blind in the affected eye unless reperfusion is achieved within the critical ischemic window2,4.
  • Neovascular Glaucoma: Retinal ischemia stimulates vascular endothelial growth factor (VEGF) release, leading to rubeosis iridis (neovascularization of the iris) and secondary angle-closure glaucoma typically appearing 2 to 8 weeks post-occlusion, managed with panretinal photocoagulation and intravitreal anti-VEGF agents1.
  • Systemic Vascular Events: CRAO patients face a substantially elevated short- and long-term risk of fatal and non-fatal cerebrovascular accidents (stroke) and myocardial infarction due to generalized atherosclerosis, necessitating aggressive secondary prevention with antiplatelet therapy, high-intensity statins, and strict blood pressure control3,4.